首頁 > 市場調查報告書 > 製藥

市場調查報告書

商品編碼

2126371

診斷試劑市場－策略分析與預測（2026-2035）

Diagnostic Reagents Market - Strategic Insights and Forecasts (2026-2035)

出版日期: 2026年08月06日 | 出版商:

Knowledge Sourcing Intelligence | 英文 172 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

預計診斷試劑市場將從 2026 年的 646 億美元成長到 2035 年的 1,302.4 億美元，複合年成長率為 8.1%。

診斷試劑市場正經歷重大變革，其驅動力來自精準醫療、分子診斷和檢查室自動化領域的模式轉移。這一市場演變的特點是，人們日益認知到診斷試劑是體外診斷行業中持續收入最高的細分市場，並且對於支持常規臨床檢測、高級分子分析和精準醫療應用至關重要。免疫診斷、分子診斷和自動化試劑系統的融合，使得診斷工作流程更加快速、靈敏且全面。隨著感染疾病、癌症和慢性病的盛行率持續上升，以及醫療機構對早期檢測和個人化治療策略的重視，全球醫療系統中進行的診斷檢測數量正在增加。市場正在大力投資多分子檢測、伴隨診斷和次世代定序技術，鞏固了診斷試劑作為現代醫療服務和精準醫療基礎要素的地位。

市場促進因素

全球感染疾病和慢性病負擔日益加重是診斷試劑市場的主要驅動力。疾病盛行率的上升導致醫院、臨床檢查室和即時檢測 (PoC) 場所對診斷檢測的需求持續成長。醫療系統正在擴展其檢測能力，以支援早期診斷、疾病監測和治療監測。這項需求推動了所有診斷技術領域對試劑的需求成長，從而導致診斷試劑使用量的持續成長。分子診斷和精準醫療的日益普及，透過對專業試劑組合的需求，進一步加速了市場成長。精準醫療需要精確的分子表徵來確定治療策略，從而持續推動對高品質分子診斷試劑和伴隨診斷的需求。醫療機構正在擴展其分子檢測能力，以支持個人化治療策略。診斷試劑製造商正在開發專業試劑組合，以支持精準醫療的不斷擴展的應用。自動化臨床檢查室的擴展推動了對自動化試劑系統的需求。檢查室自動化減少了人工操作，促進了工作流程的標準化，從而創造了對專為高通量分析儀和整合系統設計的試劑的需求。醫療機構正加大檢查室現代化改造的投入，以應對人手不足和日益成長的檢測量。診斷試劑生產商正在開發針對自動化工作流程最佳化的試劑，以滿足不斷成長的需求。診斷平台的技術進步正在提升檢測效能和檢查室效率。生物標記發現、多重檢測和人工智慧驅動的檢測工作流程的持續創新，正在提升診斷能力並拓展臨床應用範圍。這些進步正在推動臨床實踐中更廣泛的應用和檢測量的增加。

市場限制因素

診斷試劑嚴格的法規核准要求構成了市場准入壁壘，並增加了製造商的研發成本。體外診斷（IVD）試劑嚴格的品質和性能標準延長了研發時間和成本。開發和檢驗新型檢測方法的高成本限制了創新，尤其對於中小型製造商而言更是如此。成熟的診斷市場中的價格壓力正在擠壓試劑製造商的利潤空間。對先進診斷檢測方法的保險報銷限制可能會阻礙某些醫療保健系統採用這些方法。影響原料的供應鏈中斷可能導致供不應求並增加成本。

分析：依產品類型
- 臨床化學試劑
- 免疫檢測試劑
- 分子診斷試劑
- 血液學試劑
- 微生物試劑
- 組織學和細胞學試劑
- 血液凝固檢驗試劑
分析：按技術
- 免疫診斷
- 分子診斷
- 臨床化學
- 血液學
- 微生物學
分析：透過臨床應用
- 感染疾病
- 瘤
- 循環系統
- 糖尿病
- 自體免疫疾病
- 其他用途
分析：最終用途：檢查室分析
- 醫院檢查室
- 獨立診斷檢查室
- 學術和研究檢查室
- 血庫
- 臨床檢查室

第9章全球診斷試劑市場：細分市場分析

依產品類型
- 臨床化學試劑
- 免疫檢測試劑
- 分子診斷試劑
- 血液學試劑
- 微生物試劑
- 組織學和細胞學試劑
- 血液凝固檢驗試劑
透過技術
- 免疫診斷
- 分子診斷
- 臨床化學
- 血液學
- 微生物學
透過使用
- 感染疾病
- 瘤
- 循環系統
- 內分泌學
- 自體免疫疾病
- 其他用途
最終用戶
- 醫院
- 診斷檢查室
- 學術研究機構
- 製藥和生物技術公司
- 血庫

第10章全球診斷試劑市場：區域分析

北美洲
歐洲
亞太地區
南美洲
中東和非洲

第11章全球診斷試劑市場：國別分析

美國
加拿大
德國
英國
法國
義大利
西班牙
日本
中國
印度
韓國
澳洲
巴西
墨西哥
沙烏地阿拉伯
南非

第12章競爭格局

市佔率分析
策略趨勢
企業合併、合作與聯盟
新產品發布

第13章：公司簡介

F. Hoffmann-La Roche Ltd.
Abbott Laboratories
Siemens Healthineers AG
Danaher Corporation
Thermo Fisher Scientific Inc.
bioMerieux
Sysmex Corporation
Becton, Dickinson and Company
Bio-Rad Laboratories, Inc.
Agilent Technologies, Inc.
Bio-Techne Corporation
Merck KGaA
QIAGEN NV
Revvity, Inc.
Fujifilm Holdings Corporation

第14章全球診斷試藥市場：商業預測分析

第15章投資與資金籌措分析

創業投資趨勢
政府資金
研發投資

第16章：未來展望

主要成長機遇
未來產業趨勢

簡介目錄

Product Code: KSI-009083

The Diagnostic Reagents Market is set to reach USD 130.24 billion in 2035, growing at a CAGR of 8.1 % from USD 64.6 billion in 2026.

The diagnostic reagents market is undergoing significant transformation driven by the paradigm shift toward precision medicine, molecular diagnostics, and laboratory automation. The market's evolution is characterized by the growing recognition that diagnostic reagents represent the largest recurring revenue segment within the in vitro diagnostics industry, essential for supporting routine clinical testing, advanced molecular analysis, and precision medicine applications. The convergence of immunodiagnostics, molecular diagnostics, and automation-compatible reagent systems is enabling faster, more sensitive, and increasingly comprehensive diagnostic workflows. Healthcare systems worldwide are expanding diagnostic testing volumes as the prevalence of infectious diseases, cancer, and chronic conditions continues to rise and healthcare providers emphasize early detection and personalized treatment strategies. The market is witnessing significant investment in multiplex molecular assays, companion diagnostic reagents, and next-generation sequencing technologies, positioning diagnostic reagents as a foundational component of modern healthcare delivery and precision medicine.

Market Drivers

The rising global burden of infectious and chronic diseases represents the primary driver for the diagnostic reagents market. Increasing disease prevalence creates sustained demand for diagnostic testing across hospitals, clinical laboratories, and point-of-care settings. Healthcare systems are expanding testing capacity to support early diagnosis, disease surveillance, and treatment monitoring. This requirement strengthens demand for reagents across all diagnostic technology segments, resulting in sustained growth in diagnostic reagent utilization. The increasing adoption of molecular diagnostics and precision medicine is further accelerating market growth through demand for specialized reagent portfolios. Precision medicine requires accurate molecular characterization to guide therapeutic decisions, creating sustained demand for high-quality molecular diagnostic reagents and companion diagnostics. Healthcare providers are expanding molecular testing capabilities to support personalized treatment strategies. Diagnostic manufacturers are developing specialized reagent portfolios to support growing precision medicine applications. The expansion of automated clinical laboratories is driving demand for automation-compatible reagent systems. Laboratory automation reduces manual intervention and improves workflow standardization, creating demand for reagents designed for high-throughput analyzers and integrated systems. Healthcare providers are investing in laboratory modernization to address workforce shortages and increasing testing volumes. Diagnostic manufacturers are developing reagents optimized for automated workflows to capture growing demand. Technological advancements in diagnostic platforms are improving assay performance and laboratory efficiency. Continuous innovation in biomarker discovery, multiplex assays, and AI-enabled laboratory workflows is enhancing diagnostic performance and expanding clinical applications. These advancements support broader clinical adoption and increased testing volumes.

Market Restraints

Stringent regulatory approval requirements for diagnostic reagents create barriers to market entry and increase development costs for manufacturers. The rigorous quality and performance standards for IVD reagents increase development timelines and costs. High development and validation costs for new assays limit innovation, particularly for smaller manufacturers. Pricing pressure in mature diagnostic markets compresses margins for reagent manufacturers. Reimbursement limitations for advanced diagnostic assays can restrict adoption in certain healthcare systems. Supply chain disruptions affecting raw materials can create shortages and increase costs.

Technology and Product Insights

The technology landscape is characterized by the growing importance of molecular diagnostics, multiplex reagents, and automation-compatible systems. Immunodiagnostics remains the dominant technology segment owing to widespread use in infectious disease, oncology, endocrinology, and autoimmune disease testing. Molecular diagnostics continues registering the highest growth supported by PCR, NGS, and companion diagnostic applications. Clinical chemistry remains essential for routine biochemical testing across hospitals and diagnostic laboratories. Hematology and microbiology technologies continue benefiting from automation and workflow optimization. The segment analysis reveals that clinical chemistry reagents account for a significant share of the market due to their extensive use in routine biochemical testing. Molecular diagnostic and immunoassay reagents are the fastest-growing segments as healthcare providers increasingly adopt precision medicine, infectious disease testing, and companion diagnostics. Hematology, microbiology, histology, cytology, and coagulation reagents continue experiencing stable demand driven by expanding laboratory testing volumes. Infectious diseases represent the largest application segment because of increasing global diagnostic testing and disease surveillance initiatives. Oncology is experiencing the fastest growth through biomarker-driven precision medicine and companion diagnostics. Hospitals and diagnostic laboratories represent the leading end-user segments, with academic and research institutes and pharmaceutical companies expanding reagent utilization. The integration of digital connectivity is becoming increasingly important as laboratories require reagents compatible with connected diagnostic ecosystems and laboratory information systems.

Competitive and Strategic Outlook

The competitive landscape features established diagnostics and life science companies alongside specialized reagent, molecular, and immunoassay providers. Roche is a global leader in diagnostic reagents with comprehensive portfolios spanning immunodiagnostics, molecular diagnostics, tissue diagnostics, and companion diagnostics supporting precision medicine. Abbott develops clinical chemistry, immunoassay, molecular diagnostic, and point-of-care reagents that support routine laboratory testing and decentralized diagnostics. Siemens Healthineers provides diagnostic reagent portfolios for clinical chemistry, immunoassays, hematology, and molecular testing integrated with advanced laboratory automation systems. Danaher offers high-performance diagnostic reagents through its life sciences and molecular diagnostics businesses, supporting infectious disease testing, genomics, and precision medicine. Thermo Fisher Scientific develops molecular biology reagents, PCR assays, sequencing reagents, immunodiagnostic products, and clinical laboratory solutions for research and diagnostics. bioMerieux specializes in microbiology reagents, molecular diagnostic assays, infectious disease testing, and antimicrobial resistance detection technologies. Sysmex develops hematology reagents, urinalysis reagents, hemostasis diagnostics, and laboratory automation solutions supporting routine clinical testing. BD provides microbiology media, molecular diagnostic reagents, specimen collection products, and infectious disease testing solutions. Companies are pursuing product portfolio expansion through innovation in multiplex molecular assays, automation-compatible reagents, and companion diagnostic products. Strategic investments in manufacturing capacity and supply chain resilience are strengthening market competitiveness. Recent key developments include Roche expanding its molecular diagnostic reagent portfolio with new PCR assays supporting infectious disease and oncology testing. Abbott introduced next-generation clinical chemistry reagents designed for high-throughput automated laboratory analyzers. Siemens Healthineers launched enhanced immunoassay reagents for cardiac biomarker and endocrine disease testing. Thermo Fisher Scientific expanded its molecular biology reagent portfolio supporting NGS workflows.

Short Conclusion

The diagnostic reagents market is positioned for sustained growth driven by the convergence of disease burden, technological innovation, and precision medicine. The recurring revenue nature of reagents creates stable demand fundamentals while innovation in molecular diagnostics and automation-compatible products opens new growth avenues. While challenges related to regulatory compliance, development costs, and pricing pressure persist, strategic investments in technology, manufacturing capacity, and product development are creating durable competitive advantages for market leaders. The long-term market outlook remains positive, with diagnostic reagents evolving into one of the largest and most critical segments within the global in vitro diagnostics industry, supporting early disease detection, personalized medicine, and improved patient outcomes across global healthcare systems.

Key Benefits of this Report

Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
Competitive positioning, strategies, and market share evaluation, and trade analysis
Revenue growth and forecast assessment across segments and regions
Company profiling including strategies, products, financials, and key developments

1. Executive Summary

1.1 Market Snapshot
1.2 Key Findings
1.3 Analyst Insights
1.4 Strategic Recommendations

2. Research Methodology

2.1 Research Design
2.2 Data Collection Methodology
2.3 Market Size Estimation
2.4 Forecasting Model
2.5 Assumptions & Limitations

3. Global Diagnostic Reagents Market Overview, Size & Forecast

3.1 Market Definition & Scope
3.2 Industry Overview
3.3 Industry Evolution
3.4 Key Market Trends
3.5 Historical Market Size Analysis (2021-2025)
3.6 Market Forecast (2026-2035)
3.7 Diagnostic Testing Volume Analysis
3.8 Reagent Utilization Analysis
3.9 Laboratory Workflow Analysis
3.10 Role of Diagnostic Reagents in Precision Diagnostics

4. Market Dynamics

4.1 Market Drivers
4.2 Market Restraints
4.3 Market Opportunities
4.4 Market Challenges

5. Industry Landscape

5.1 Industry Value Chain Analysis
5.2 Pricing Analysis
5.3 Reimbursement Landscape

6. Innovation Landscape

6.1 Emerging Technologies
6.2 Product Innovation
6.3 Multiplex Reagent Development
6.4 AI-Enabled Diagnostic Workflows
6.5 Companion Diagnostic Reagents
6.6 Next-Generation Molecular Reagents
6.7 Technology Roadmap

7. Regulatory Landscape

7.1 Regulatory Framework
7.2 Approval Pathways
7.3 Compliance Requirements

8. Global Diagnostic Reagents Market Landscape Analysis

8.1 Analysis by Product Type
- 8.1.1 Clinical Chemistry Reagents
- 8.1.2 Immunoassay Reagents
- 8.1.3 Molecular Diagnostic Reagents
- 8.1.4 Hematology Reagents
- 8.1.5 Microbiology Reagents
- 8.1.6 Histology & Cytology Reagents
- 8.1.7 Coagulation Reagents
8.2 Analysis by Technology
- 8.2.1 Immunodiagnostics
- 8.2.2 Molecular Diagnostics
- 8.2.3 Clinical Chemistry
- 8.2.4 Hematology
- 8.2.5 Microbiology
8.3 Analysis by Clinical Application
- 8.3.1 Infectious Diseases
- 8.3.2 Oncology
- 8.3.3 Cardiology
- 8.3.4 Diabetes
- 8.3.5 Autoimmune Diseases
- 8.3.6 Other Applications
8.4 Analysis by End-use Laboratory
- 8.4.1 Hospital Laboratories
- 8.4.2 Independent Diagnostic Laboratories
- 8.4.3 Academic & Research Laboratories
- 8.4.4 Blood Banks
- 8.4.5 Physician Office Laboratories

9. Global Diagnostic Reagents Market Segment Analysis (2021-2035)

9.1 By Product Type
- 9.1.1 Clinical Chemistry Reagents
- 9.1.2 Immunoassay Reagents
- 9.1.3 Molecular Diagnostic Reagents
- 9.1.4 Hematology Reagents
- 9.1.5 Microbiology Reagents
- 9.1.6 Histology & Cytology Reagents
- 9.1.7 Coagulation Reagents
9.2 By Technology
- 9.2.1 Immunodiagnostics
- 9.2.2 Molecular Diagnostics
- 9.2.3 Clinical Chemistry
- 9.2.4 Hematology
- 9.2.5 Microbiology
9.3 By Application
- 9.3.1 Infectious Diseases
- 9.3.2 Oncology
- 9.3.3 Cardiology
- 9.3.4 Endocrinology
- 9.3.5 Autoimmune Diseases
- 9.3.6 Other Applications
9.4 By End User
- 9.4.1 Hospitals
- 9.4.2 Diagnostic Laboratories
- 9.4.3 Academic & Research Institutes
- 9.4.4 Pharmaceutical & Biotechnology Companies
- 9.4.5 Blood Banks

10. Global Diagnostic Reagents Market Geographical Analysis (2021-2035)

10.1 North America
10.2 Europe
10.3 Asia-Pacific
10.4 South America
10.5 Middle East & Africa

11. Global Diagnostic Reagents Market Country Analysis (2021-2035)

11.1 United States
11.2 Canada
11.3 Germany
11.4 United Kingdom
11.5 France
11.6 Italy
11.7 Spain
11.8 Japan
11.9 China
11.10 India
11.11 South Korea
11.12 Australia
11.13 Brazil
11.14 Mexico
11.15 Saudi Arabia
11.16 South Africa

12. Competitive Landscape

12.1 Market Share Analysis
12.2 Strategic Developments
12.3 Mergers & Acquisitions, Partnerships & Collaborations
12.4 Product Launches

13. Company Profiles

13.1 F. Hoffmann-La Roche Ltd.
- 13.1.1 Company Overview
- 13.1.2 Financials
- 13.1.3 Product Portfolio
- 13.1.4 Recent Developments
13.2 Abbott Laboratories
- 13.2.1 Company Overview
- 13.2.2 Financials
- 13.2.3 Product Portfolio
- 13.2.4 Recent Developments
13.3 Siemens Healthineers AG
- 13.3.1 Company Overview
- 13.3.2 Financials
- 13.3.3 Product Portfolio
- 13.3.4 Recent Developments
13.4 Danaher Corporation
- 13.4.1 Company Overview
- 13.4.2 Financials
- 13.4.3 Product Portfolio
- 13.4.4 Recent Developments
13.5 Thermo Fisher Scientific Inc.
- 13.5.1 Company Overview
- 13.5.2 Financials
- 13.5.3 Product Portfolio
- 13.5.4 Recent Developments
13.6 bioMerieux
- 13.6.1 Company Overview
- 13.6.2 Financials
- 13.6.3 Product Portfolio
- 13.6.4 Recent Developments
13.7 Sysmex Corporation
- 13.7.1 Company Overview
- 13.7.2 Financials
- 13.7.3 Product Portfolio
- 13.7.4 Recent Developments
13.8 Becton, Dickinson and Company
- 13.8.1 Company Overview
- 13.8.2 Financials
- 13.8.3 Product Portfolio
- 13.8.4 Recent Developments
13.9 Bio-Rad Laboratories, Inc.
- 13.9.1 Company Overview
- 13.9.2 Financials
- 13.9.3 Product Portfolio
- 13.9.4 Recent Developments
13.10 Agilent Technologies, Inc.
- 13.10.1 Company Overview
- 13.10.2 Financials
- 13.10.3 Product Portfolio
- 13.10.4 Recent Developments
13.11 Bio-Techne Corporation
- 13.11.1 Company Overview
- 13.11.2 Financials
- 13.11.3 Product Portfolio
- 13.11.4 Recent Developments
13.12 Merck KGaA
- 13.12.1 Company Overview
- 13.12.2 Financials
- 13.12.3 Product Portfolio
- 13.12.4 Recent Developments
13.13 QIAGEN N.V.
- 13.13.1 Company Overview
- 13.13.2 Financials
- 13.13.3 Product Portfolio
- 13.13.4 Recent Developments
13.14 Revvity, Inc.
- 13.14.1 Company Overview
- 13.14.2 Financials
- 13.14.3 Product Portfolio
- 13.14.4 Recent Developments
13.15 Fujifilm Holdings Corporation
- 13.15.1 Company Overview
- 13.15.2 Financials
- 13.15.3 Product Portfolio
- 13.15.4 Recent Developments